Active clinical trial

Sub-Clinical Paroxysmal EEG Abnormalities in Alzheimer's Disease

Study Status: 
Active
Study Description: 

Coming soon!

4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2

Study Status: 
Active
Study Description: 

Coming soon!

Neural and Cognitive Changes Associated with Mental Training in Older Adults

Study Status: 
Active
Study Description: 

This study examines the effect of cognitive enhancement programs on age related changes in memory and attention.

 

ELIGIBLE?
We are seeking healthy, right-handed adults between the ages of 65-80. If eligible, you will receive 8 professional cognitive training sessions free of charge. You will also receive take-home exercises to supplement your training classes, and will be asked to complete these exercises daily for the duration of the 8-week program.

 

You will come in for 5 study visits: before the course, after the course, and at 6, 12, and 24 months after the start of the study. These study visits include surveys, cognitive tests, and a total of 3 fMRI scans. In addition to the cognitive training courses, participants will receive compensation up to $275 for completing all study visits.

Study Coordinator(s): 

Samantha Krivensky

Tel:  617-726-6205

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Study Status: 
Active
Study Description: 

 

Our Research. Your Story.

Research is happening at Massachusetts General Hospital (MGH) that is focused on learning about the cognitive abilities, personality, and other traits of people who have more than one blood relative affected with Frontotemporal Degeneration (FTD), Alzheimer’s disease, and related disorders.

 

You Can Contribute to the Cause

Diagnosis of FTD is often challenging and current treatment options are limited.  We hope that the scientific research we are conducting at MGH will change that for future generations.

 

We are seeking people or relatives of people who have been diagnosed with FTD, Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD) or FTD with Amyotrophic Lateral Sclerosis (ALS), or have a relative with a mutation in the three most common genes associated with FTD (MAPT, PGRN/GRN, C9ORF72). By listening and learning about you and your family, we hope the knowledge gained from this work will help researchers and doctors to learn if there are certain cognitive or behavioral traits that can help predict the development of these disorders.

 

More information about the study is attached.

Study Coordinator(s): 

Katie Kelly

Tel:  617-726-6205

Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)

Study Status: 
Active
Study Description: 

 

Our Research. Your Story.

Research is happening at Massachusetts General Hospital (MGH) that is focused on learning about the cognitive abilities, personality, and other traits of people who have more than one blood relative affected with Frontotemporal Degeneration (FTD), Alzheimer’s disease, and related disorders.

 

You Can Contribute to the Cause

Diagnosis of FTD is often challenging and current treatment options are limited.  We hope that the scientific research we are conducting at MGH will change that for future generations.

We are seeking people who are members of families with a known mutation in one of the three major FTLD related genes: MAPT, PGRN, and C9ORF72.  By listening and learning about you and your family, we hope the knowledge gained from this work will help researchers and doctors to learn if there are certain cognitive or behavioral traits that can help predict the development of these disorders.

 

More information about the study is attached!

Study Coordinator(s): 

Samantha Krivensky

Tel:  617-726-6205

Connectome Imaging in Aging and Dementia

Study Status: 
Active
Study Description: 

We're looking for adults with AD, FTD, MCI or cognitive complaints, ages 50-95!

 

The purpose of this research study is to look at brain connectivity in a variety of people with memory problems, including people with complaints about their memory and people diagnosed with a neurodegenerative disease, including Alzheimer’s disease (AD), fronto-temporal dementia (FTD), and mild cognitive impairment (MCI).

 

What to expect:

•     one 3-hour visit

•     Participants watch a movie during a one hour brain scan (MRI)

•     Questionnaires and memory testing

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-278-0383

The ENGAGE Study

Study Status: 
Active
Study Description: 

We are recruiting patients for the ENGAGE Study, which is evaluating the safety and efficacy of aducanumab (BIIB037) in slowing cognitive and functional impairment in patients with early Alzheimer’s disease.

 

Aducanumab is a human monoclonal antibody against ß-amyloid, which is thought to bind to and eliminate the soluble oligomers and insoluble fibrils (both of which are believed to be toxic) that form in the brains of people with Alzheimer’s disease. The total study duration is approximately 4 years. Once every 4 weeks, participating patients will receive intravenous infusions of low- or high-dose aducanumab or placebo for 76 weeks in the placebo-controlled phase, followed
by low- or high-dose aducanumab for 100 weeks in the long-term extension phase.

 

More information about the study is attached.

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-278-0383

A Multi-Center, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Impact of Nasal-Inhaled Insulin in Participants with Mild Memory Impairment and Early Alzheimer's Disease (SNIFF)

Study Status: 
Active
Study Description: 

What is the SNIFF Study?

The purpose of the SNIFF study is to find out whether insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer's disease (AD).  The rationale behind the study is growing evidence that insulin carries out multiple functions in the brain and that poor regulations of insulin may contribute to the development of AD. Insulin resistance, reduced cerebrospinal fluid insulin levels, and reduced brain insulin signals have been found in AD patients, suggesting that a therapy aimed at correcting these deficiences may be beneficial.

 

A study flyer with more details is attached.

Study Coordinator(s): 

Nancy Coppelman

Tel:  617-278-0383

A Multi-Center, Double-Bind, Placebo-Controlled Phase IIa Study to Evaluate an Investigational Medicine to Treat Mild-Stage Alzheimer's Disease (CONNECT)

Study Status: 
Active
Study Description: 

The CONNECT study will test whether an oral, experimental drug, AZD0530 (Saracatinib), will slow progression in mild-stage Alzheimer's disease (AD). Although the cause of AD is unknown, several lines of evidence suggest that a peptide known as beta-amyloid plays a central role.  Convergent evidence in recent years has yielded a refinement of the "amyloid hypothesis", suggesting that neurotoxicity of beta-amyloid oligomers leads to Alzheimer's disease.

 

Researchers are looking for people who:

-- are 55-85 years of age,

-- have a diagnosis of mild Alzheimer's disease,

-- are willing to undergo a variety of clinic assessments,

-- have a study partner willing to attend clinic visits and have at least 10 hours/week of contact with study participant.

 

A study flyer with more details is attached.

Study Coordinator(s): 

Nancy Coppelmen

Tel:  617-278-0383

Syndicate content